Virtus LifeSci Biotech Clinical Trials ETF
19 hedge funds and large institutions have $10.2M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Holders
19
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$2.89M | |
| 2 | +$1.39M | |
| 3 | +$507K | |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$429K |
| 5 |
Morgan Stanley
New York
|
+$208K |
Top Sellers
| 1 | -$859K | |
| 2 | -$758K | |
| 3 | -$428K | |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$99K |
| 5 |
LPL Financial
San Diego,
California
|
-$4.92K |
